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facilitate CKD recognition across the 
broad landscape of the health-care sys-
tem and to promote the provision of 
CKD-specifi c safe care are lacking and 
should be developed. Nevertheless, the 
findings of Hug  et al. , 6 and their 
 endorsement of the use of CPOE sys-
tems, are important steps toward increas-
ing the medical community ’ s awareness 
of the sensitivity of patients with CKD to 
medication administration and toward 
improving the safety of their care. As 
nephrologists, we should expand beyond 
our traditional  ‘ nephrocentric ’ view of 
the universe. Eff orts to prevent nephro-
toxicity or to slow progression of CKD 
should not be abandoned, but a more 
holistic approach to enhancing patient 
safety should become a priority of our 
collective practice. 
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 Increased oxidative stress, resulting from 
an imbalance between oxidant production 
and antioxidant reserves, is highly preva-
lent in a wide variety of chronic kidney 
diseases (CKD). 1,2 Oxidative, as well as 
carbonyl, stress in uremic states often 
incites damage to biologically important 
macromolecules, including proteins, lip-
ids, carbohydrates, and nucleic acids, and 
causes them to undergo structural modi-
fi cations, which leads to generation of the 
so-called advanced oxidation protein 
products (AOPPs), advanced lipoxidation  
end products, and advanced glycation end 
products. AOPPs are a family of oxidized, 
dityrosine-containing protein products 
generated during excessive production of 
oxidants and oft en carried by albumin 
 in vivo . 3 Accumulation of plasma and 
renal AOPPs is a common pathologic 
fi nding in dialysis patients, as well as in 
patients with diabetes and metabolic syn-
drome. Accordingly, the levels of plasma 
and tissue AOPPs are postulated as a 
reliable marker to estimate the degree 
of oxidant-mediated protein damage in 
uremic patients. 
 Emerging evidence indicates that 
AOPPs may not merely be a surrogate 
marker for oxidative stress in the injured 
kidney; they are actually a new class of 
renal pathogenic mediators as well. 
Clinical studies have shown that AOPP 
level is a strong predictor for the progno-
sis of IgA nephropathy. 4 In experimental 
models, chronic accumulation of plasma 
AOPPs in rats is associated with an 
increase in urinary protein excretion, 
decreased creatinine clearance, exagger-
ated macrophage infi ltration, and aggra-
vated glomerulosclerosis in remnant 
kidney and diabetic nephropathy. 5 Given 
that AOPPs are capable of inducing renal 
expression of proinfl ammatory cytokines 
and activate nuclear factor-  B signaling, 
their detrimental eff ects are oft en thought 
to result from the activation of a redox-
sensitive infl ammatory pathway . Not sur-
prisingly, AOPPs are also implicated in 
the pathogenesis of atherosclerosis and 
cardiovascular disorders in patients with 
chronic renal insuffi  ciency. In fact, AOPPs 
have been identifi ed as an independent 
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 Advanced oxidation protein 
products: a causative link 
between oxidative stress 
and podocyte depletion 
 Youhua  Liu 1   
 Advanced oxidation protein products (AOPPs), a protein biomarker of 
increased oxidative stress, are elevated in uremic patients. Zhou  et al. 
demonstrate that chronic administration of AOPPs induces podocyte 
apoptosis and proteinuria in normal rats via a cascade of signaling 
events. This study for the first time establishes a causative link between 
oxidative stress and podocyte depletion and could have broad 
implications in our understanding of the pathogenic mechanism 
of proteinuria. 
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risk factor for atherosclerotic cardiovas-
cular events in CKD. 6  In vitro studies 
reveal that AOPPs induce vascular 
endothelial and smooth muscle cell dys-
function by activating nuclear factor-  B 
and p38 mitogen-activated protein kinase 
signaling 7,8 and therefore could directly 
contribute to the excessive cardiovascular 
risk in uremic patients. 
 Zhou and colleagues 9 (this issue) now 
report that chronic administration of 
AOPP-modifi ed albumin by intravenous 
injections results in intrarenal accumula-
tion and dramatically induces podocyte 
apoptosis and proteinuria in normal, 
healthy rats. Consistently, incubation of 
cultured podocytes with AOPP-modifi ed 
albumin at a concentration comparable to 
that in the blood circulation of uremic 
patients also triggers the death of podo-
cytes  in vitro . It is particularly interesting 
that glomerular podocytes appear to be 
especially vulnerable to AOPP exposure, 
and podocyte apoptosis occurs at a rate of 
an average of 3.5 cells per glomerular 
cross-section at 5 weeks aft er injection, 9 
which is about 17 % of the entire glomeru-
lar podocyte population in that setting. 
Th is magnitude of podocyte apoptosis 
 in vivo seems astonishing, as it is approxi-
mately 10- to 100-fold more frequent than 
that reported in most publications of other 
kidney disease models. Notably, such an 
eff ect of AOPPs on podocytes appears not 
to be related to their particular formula-
tion  in vitro , because AOPPs isolated from 
the serum of uremic patients display an 
almost identical potency in triggering 
podocytes ’ apoptotic death. 9 Th is study 
unambiguously establishes a causative 
link between oxidative stress and podo-
cyte apoptosis and depletion , and illus-
trates that elevated levels of AOPPs play 
a direct role in the pathogenesis of pro-
teinuria in CKD. 
 Podocytes and their foot processes are an 
integral component of the glomerular fi ltra-
tion barrier. Increasing evidence suggests 
that disruption of podocyte integrity plays 
an essential role in causing defective 
glomerular fi ltration and proteinuria in 
the majority of genetic and acquired forms 
of glomerular diseases. In the pathologic 
setting, podocytes may respond to injuri-
ous stimuli in diff erent ways, including 
hypertrophy, dediff erentiation, epithelial-
to-mesenchymal transition, detachment, 
and apoptosis. 10,11 It remains a mystery 
what determines the ultimate path a 
podocyte might choose to take in response 
to a particular insult. The differential 
responses of podocytes may not only 
depend on the severity and / or duration of 
a specifi c injury but are also likely deter-
mined by the characteristic nature of that 
insult. In this regard, AOPPs appear to be 
a particularly potent inducer of podocyte 
apoptosis both  in vivo and  in vitro . Need-
less to say, podocyte depletion aft er apop-
totic death in the glomeruli would 
inevitably cause impaired glomerular fi l-
tration, leading to the development of 
proteinuria and glomerulosclerosis. 
 Th e mechanism by which AOPPs pro-
voke podocytes to undergo apoptosis is 
eloquently elucidated by the combined  in 
vitro and  in vivo approach of Zhou  et al. 9 
( Figure 1 ), which represents one of the 
many strengths of their study . Th ey found 
that an elevated level of AOPPs induces 
intracellular superoxide (O 2   −   ) generation 
in podocytes by a mechanism involving 
nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidase. Intriguingly, 
AOPPs not only activate NADPH oxidase 
through a protein kinase C-dependent 
pathway but also induce the expression of 
major components of this enzyme complex 
 in vivo and  in vitro , thereby leading to an 
excessive generation of intracellular super-
oxide, which in turn provokes the classical 
p53 / Bax / caspase-dependent apoptosis 
pathway ( Figure 1 ). Hence, AOPPs induce 
podocyte apoptosis via a cascade of signal-
ing events and ultimately couple oxidative 
stress to a principal, p53-dependent cell-
death machinery. 
 Th e present study also raises more new 
questions. One fundamental issue to be 
addressed is exactly how AOPPs transmit 
their signals across the plasma membrane 
to elicit cellular activities. One can assume 
that this probably requires a transmem-
brane receptor for AOPPs. Thus far, 
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 Figure 1  |  Oxidative stress leads to podocyte depletion in CKD via AOPPs. Chronic 
accumulation of AOPPs in CKD, as well as in diabetes mellitus and metabolic syndrome, triggers 
a cascade of signaling events that lead to protein kinase C / nicotinamide adenine dinucleotide 
phosphate oxidase activation, superoxide (O 2 
  −   ) generation, p53 / Bax / caspase activation, and 
finally podocyte apoptosis and depletion. Whether AOPPs transmit their signals via binding to their 
own (novel) receptor, or via the receptor for advanced glycation end products (RAGE) and CD36, 
remains to be determined. AOPPs, advanced oxidation protein products; CKD, chronic kidney 
disease; NADPH, nicotinamide adenine dinucleotide phosphate; PKC, protein kinase C. 
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whether there is a dedicated, unique 
transmembrane receptor for AOPPs 
remains an open question. Earlier studies 
have shown that AOPPs are capable of 
using the receptor for advanced glycation 
end products (RAGE) for their signaling 
in vascular endothelial cells. 7 Likewise, 
AOPPs could use CD36, a class B trans-
membrane multiligand scavenger receptor 
that binds to oxidized proteins and is 
induced in renal tubular epithelial cells in 
CKD, for transmitting their signals. 12 
In this context, it is conceivable that 
AOPPs may induce podocyte apoptosis 
by using RAGE or CD36 receptors. As 
both RAGE and CD36-knockout mice 
are currently available, one might antici-
pate a defi nite answer to this postulation 
in the near future. 
 Th e fi ndings presented by Zhou and 
colleagues could have broad implications 
in our understanding of the pathogenesis 
of podocyte depletion and proteinuria in 
CKD. As end-stage kidney disease is now 
recognized to be associated with states 
of increased oxidative stress, AOPP-
mediated podocyte apoptosis would 
undoubtedly play a critical role in pro-
moting proteinuria and accelerating 
glomerulosclerosis, although it remains 
uncertain whether this pathway is active 
and operated in the early stage of kidney 
disease. In addition, many pathogenic 
factors, such as hyperglycemia, angi-
otensin II, and transforming growth fac-
tor-  1, are able to trigger intracellular 
superoxide generation. Th erefore, the 
signal cascade elucidated in this study 
might potentially be a convergent path-
way leading to podocyte depletion in 
CKD patients. 
 Given that inhibition of NADPH oxidase 
with apocynin eff ectively protects podo-
cytes from AOPP-mediated apoptosis  in 
vivo and  in vitro , strategies aimed at reduc-
ing oxidative stress might prevent podocyte 
loss, thereby blocking the progression of 
CKD in the clinical setting . 
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 It is well known that cardiovascular dis-
ease is a signifi cant cause of death in renal 
transplant patients and may account for 
47 % of all deaths in this population. 1 Th e 
increased propensity for cardiovascular 
disease is thought to stem from the inter-
play of immunosuppressive medications, 
most notably calcineurin inhibitors and 
corticosteroids. Th e sequelae of taking 
these medications in the post-transplan-
tation period include the development of 
weight gain, hyperlipidemia, hyperten-
sion, and glucose intolerance, which in 
combination describe metabolic syn-
drome (MS). 2,3 In addition to accelerating 
post-transplantation cardiovascular dis-
ease, MS has been thought to be a risk 
factor for chronic renal allograft  dysfunc-
tion. 4 MS has been reported to be as high 
as 57 % in the fi rst year following trans-
plantation. 5 MS is a dynamic disorder, 
and its development probably arises 
from the interaction of genetic makeup 
and lifestyle. Nafar and colleagues 6 
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 Mediterranean diets: are they 
practical in the Western world ? 
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 The incidence of metabolic syndrome (MS) in renal transplant patients is 
unacceptably high. Dietary intake may ameliorate or worsen the 
potential for the development of MS.  The choice of immunosuppression 
also plays a role. Continued effort to find beneficial dietary 
combinations is essential while ongoing research evolves to find 
newer immunosuppressive medications with less adverse metabolic 
side effects. 
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